Cargando…
Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
Many cancer treatments are associated with serious side effects, while they often only benefit a subset of the patients. Therefore, there is an urgent clinical need for tools that can aid in selecting the right treatment at diagnosis. Here we introduce simulated treatment learning (STL), which enabl...
Autores principales: | Ubels, Joske, Sonneveld, Pieter, van Beers, Erik H., Broijl, Annemiek, van Vliet, Martin H., de Ridder, Jeroen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063966/ https://www.ncbi.nlm.nih.gov/pubmed/30054467 http://dx.doi.org/10.1038/s41467-018-05348-5 |
Ejemplares similares
-
VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma
por: Broijl, Annemiek, et al.
Publicado: (2021) -
A data-driven interactome of synergistic genes improves network-based cancer outcome prediction
por: Allahyar, Amin, et al.
Publicado: (2019) -
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials
por: Chen, Yan‐Ting, et al.
Publicado: (2021) -
Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study
por: Bennink, Christine, et al.
Publicado: (2023) -
V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
por: Mutsaers, Pim, et al.
Publicado: (2021)